The approved therapeutic drugs for clinical AD treatments are only acetylcholinesterase (AChE) inhibitors, which are developed based on the “cholinergic hypothesis”, which suggests that acetylcholine plays a vital role in learning and memory; therefore, dysfunctions in the brain neurons associated with acetylcholine may contribute to cognitive decline. Here, ACHE is linked to Mental deterioration.